A Comparison of FDA and EMA drug approval: Implications for drug development and cost of care

ONCOLOGY (United States)

Volumn 27, Issue 12, 2013, Pages

  Howie, Lynn J ^a   Hirsch, Bradford R ^a   Abernethy, Amy P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ERYTHROPOIETIN; GENERIC DRUG; PAZOPANIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; UNITED STATES;

EID: 84890482101     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-28. Erratum in: J Natl Cancer Inst. 2011;103:699.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165-74.
3. The FDA and slower cures. Wall Street Journal. February 28, 2011.
4. FDA launches 7 initiatives with European drug regulators. Available from: http://www.cancernetwork.com/articles/fda-launches-7-initiatives-european-drug-regulators. Accessed November 14, 2013.
5. Fast track, breakthrough therapy, accelerated approval and priority review. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewth erapies/ucm128291.htm#accelerated. Accessed November 15, 2013.
6. Regorafenib. Available from: http://www.fiercebiotech.com/tags/regorafenib. Accessed November 14, 2013.
7. Zakaria F. Finding a strategy for growth. Washington Post. January 24, 2011.
8. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the united states than in Europe. Health Aff (Millwood). 2011;7:1375-81.
9. Downing NS, Aminawung JA, Shah ND. Regulatory review of novel therapeutics-comparison of three regulatory agencies. N Engl J Med. 2012;366:2284-93.
10. NICE and the NHS: where NICE guidance applies. Available from: http://www.nice.org.uk/aboutnice/whatwedo/niceandthenhs/nice_and_the_nhs.jsp. Accessed November 15, 2013.
11. How we regulate: what principles inform the decisions. Available from: http://www.mhra.gov.uk/Howweregulate/Whatprinciplesinformthedecisions/. Accessed November 15, 2013.
12. Trotta F, Leufkens HG, Schellens JH, et al. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol. 2011;29:2266-72.
13. Hirsch BR, Lyman GH. Will biosimilars gain momentum? J Natl Compr Canc Netw. 2013;11:1291-7.
14. Guidance for industry. Biosimilars: questions and answers regarding the implementation of the Biologics Price Competition and Innovation Act of 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM273001.pdf. Accessed November 15, 2013.
15. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol. 2012;7(suppl 1):S29-S34.
16. Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012;4:95-105.
17. Development and approval processes: biologics. Available from: http:\\www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/Appr ovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed November 15, 2013.
18. Teva announces FDA grants approval for tbo-filgrastim for the treatment of chemotherapy-induced neutropenia. Available from: http://www.tevapharm.com/Media/News/Pages/2012/1730014.aspx. Accessed November 16, 2013.
19. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2013;11:1266-90.
20. Tbo-Filgrastim. Presented by Teva Pharmaceuticals at the AJMC Patient Centered Oncology Care Conference; November 14, 2013; Baltimore.
21. Megerlin F, Lopert R, Taymor K, Trouvin JH. Biosimilars and the European experience: implications for the United States. Health Aff (Millwood). 2013;32:1803-10.
22. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Accessed November 20, 2013.
23. Approved drugs: pazopanib. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm302090.htm. Accessed November 16, 2013.
24. Pazopanib: EPAR product information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001141/ WC500094272.pdf. Accessed November 16, 2013.
25. Bottomley A, Jones D, Claasens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer. 2009;45:347-53.
26. Sutter S. Patient-reported outcomes tools should be symptom specific, FDA says. The Pink Sheet. November 11, 2013.
27. Moran N. Incyte comes of age with JAK inhibitor approval. Nature Biotechnol. 2012;30:3-5.
28. Pignatti F. Implementing a national cancer clinical trials system for the 21st century: workshop #2, Institute of Medicine. February 11, 2013. [video] Available from: http://www.iom.edu/Activities/Disease/NCPF/2013-FEB-11/Day%202/Session%206/34-Pignatti.aspx. Accessed November 20, 2013.